For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.
When that moment arrives, there's rarely a middle ground: a positive result can send shares sharply higher and validate years of spending, while a miss can wipe out most of the market cap overnight. That's what makes these "binary catalysts" so important to track, and so risky to hold through.
